Download Free Medical The Impact of COVID-19 on Cancer Treatment in Germany PowerPoint Presentation

The Impact of COVID-19 on Cancer Treatment in Germany PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This report titled, “The Impact of COVID-19 on Cancer Treatment in Germany” is by the IQVIA Institute and is a voluntary, unpaid, IQVIA-sponsored survey of Oncologists, Hem-oncologists and Onco-surgeons examining the impact of coronavirus COVID-19 on cancer treatment in Germany.

Tags : Healthcare, Oncology, cancer, Cancer Treatment, COVID-19, Germany, Oncologists, Hem-oncologists, Onco-surgeons

Published on : Jul 20, 2020 | Views : 2455 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

© 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. Germany Report Impact of COVID-19 on cancer treatment
Slide 2-

1 Overview What is the purpose of this report? The purpose of this report is to determine if there has been any changes reported in the treatment of cancer across Germany now as restrictions ease and exit lockdown We will be comparing what Onco Specialists are telling us now (Wave 2) vs what they said at the start of the pandemic (Wave 1) The information gathered from IQVIA’s Onco Specialists community provides insight and understanding into key topics such as: The impact of cancer patient visits at different phases during COVID -19 Interaction via telehealth/ remote consultations during difference phases of the pandemic What specific type of treatment practices are impacted? What are the current changes anticipated now that restrictions are being relaxed? What pharma/biotech initiatives can help Onco Specialists deliver the best care possible their patients What communication channels are pharma companies using to communicate with Onco Specialists? How and When was the data collected? Onco Specialists were invited to participate via email and the survey was hosted on DocNet – IQVIA’s internal and secure online community for healthcare professionals This survey was not sponsored by any IQVIA client/customer. IQVIA was not compensated in any way for this survey Data collection occured from the 17th of June – 22nd of June 2020 (Wave 2) We will be comparing results with our Wave 1 survey that took place between 2nd of April – 8th of April 2020 (Wave 1) Impact of COVID-19 on cancer treatment – Germany June 2020. Copyright 2020 IQVIA. All rights reserved.
Slide 3-

2 3% Hematologist 94% Hem-Oncologist 3% Oncologists Wave 2 (n=36) Sample split Q0. Which of the following best describes your primary medical specialty? Across Germany, 36 Onco Specialists voluntarily participated in a 3 mins survey that IQVIA hosted on DOCNET Impact of COVID-19 on cancer treatment – Germany June 2020. Copyright 2020 IQVIA. All rights reserved.
Slide 4-

3 Impact of COVID-19 on cancer treatment – Germany June 2020. Copyright 2020 IQVIA. All rights reserved. There has been a spike in the number of cancer patients seen per week as restrictions ease in Germany but is still significantly lower than pre COVID days Average* number of cancer patients seen prior to COVID-19 outbreak Average number of cancer patients seen per week (Wave 1) Average number of cancer patients seen last week (Wave 2) 141 Patients 75 Patients 112 Patients Pandemic Outburst Exiting Lockdown Q1: After the COVID-19 outbreak, are you seeing fewer hematology/oncology patients per week? Wave 2 (n=20) Wave 1 (n=26) Impact on number of cancer patient seen due to COVID 19 outbreak * Weighted average of Wave 1 and Wave 2 Note: All numbers shown in slide are absolute numbers (number of patients)
Slide 5-

4 Impact of COVID-19 on cancer treatment – Germany June 2020. Copyright 2020 IQVIA. All rights reserved. Restrictions led to a spike in remote consultations (5% to 21%), however with time, Onco Specialists believe this would not impact much in their practice 5% Prior to COVID outbreak 21% During lockdown 12% Post lockdown 11% When COVID won’t exist Q2: Could you please estimate the typical proportion of interaction via telehealth/remote consultation in the following time period? % proportion of patients on remote consultations
Slide 6-

5 Impact of COVID-19 on cancer treatment – Germany June 2020. Copyright 2020 IQVIA. All rights reserved. A significant level of improvement was observed vs wave 1 on lesser patient referrals, lesser biopsies and delay in surgeries Wave 1 Wave 2 73% 67% 57% 44% 39% Less number of referrals to hematologists/ oncologists Lesser biopsy/ diagnosis Q3: What according to you is the impact on cancer treatment practice amidst the COVID-19 crisis? Wave 2 (n=36) Wave 1 (n=30) Impact of COVID 19 crisis on cancer treatment 61% Delay in surgeries
Slide 7-

6 6% Patients Physicians Hospitals Impact of COVID-19 on cancer treatment – Germany June 2020. Copyright 2020 IQVIA. All rights reserved. Increased remote consultations, limited visitor policies and change in treatment protocol to include orals/SC and self administrable therapies are some of the key practice changes seen by Onco Specialists Change in treatment protocol to introduce oral cancer medications Change treatments to include cancer medications which patients can self- administer Addition of more surgery days/ chemo cycles Increased daily working hours Increased frequency of remote consultations Refer patients to other facilities due to lack of hospital infrastructure 22% 22% 22% 28% 69% Limited visitor policy except in case of end of life circumstances 78% 44% Q4: What key changes are you currently seeing in your practice setting as we see restrictions being relaxed to some extent now? Allow in-person visits primarily for critical and/or newly diagnosed cancer patients
Slide 8-

7 Impact of COVID-19 on cancer treatment – Germany June 2020. Copyright 2020 IQVIA. All rights reserved. To maintain social distancing, E-mails, virtual meetings and post/direct mail have become current new modes to connect with Onco Specialists Current modes of communication Physicians’ expectations from pharma companies E-mail Virtual Meetings Post / Direct Mail Phone Call No Contacts Q5: What initiatives can pharma/biotech take in order to help you manage increased cancer patients in the coming few months? Q6: In the current COVID-19 scenario, which of the following communication channels are pharma companies using to communicate with you? 92% 61% 61% 56% 3% Tips on how to best communicate remotely with the rest of their practice and patients 64% 58% Availability of an online resource center which can be accessed for product related information Update on the availability of critical oncology drugs for their patients 53% To increase patient support services 44% Webinars 53% Messaging app 14% Face to face 22%
Slide 9-

8 DISCLAIMER Sample size is not representative at country level. Sample composition varies at the country level. Sample sizes are different between Wave 1 and Wave 2 – Its important to keep that in mind when making comparisons between the changes observed in responses. In addition, some Oncology specialists might be responding to questions based on what they have actually experienced, whilst others may be based on what they believe might happen. This was a pulse survey. The questions asked are intended to provide top level insight into what Oncology specialists across the country are experiencing. Impact of COVID-19 on cancer treatment – Germany June 2020. Copyright 2020 IQVIA. All rights reserved.
Slide 10-

© 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. For further information, please contact: GlobalPI@IQVIA.com

User Presentation
Related Presentations

2019 R&D Achievements New product launches, clinical trial activity, and investments

By: docshare
Views: 1842

The Global Use of Medicine in 2019 and Outlook to 2023

By: docshare
Views: 1819

Forest Bathing and Forest Medicine - The Impact of Shinrin-Yoku on Wellness

By: docshare
Views: 3116

Data exclusivity, market protection, orphan and paediatric rewards

By: docshare
Views: 1704

PUBLIC HEALTH PROGRAMMES and PHARMACOVIGILANCE

By: docshare
Views: 2390

Genetic Testing

By: JenniferDwayne
Views: 2632

Evidence-Based Practices for Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome

By: drdwayn
Views: 1727

Understanding Cancer

By: drdwayn
Views: 1981

Introduction: Cervical Cancer Screening

By: drdwayn
Views: 2881

Cell phones and brain cancer

By: drdwayn
Views: 2162

docshare

About : I am a passionate medical marketing professional with hands on experience in healthcare digital marketing.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : India
Website :

HEALTH A TO Z